Genprex reports positive preclinical gene therapy data
Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The event, which took place from October 23-25, 2024, in Barcelona, Spain, saw Genprex's research collaborators present findings on Reqorsa's potential in treating various forms of cancer resistant to other therapies.
The presented studies focused on the effectiveness of Reqorsa in combating KRAS G12C mutant lung cancer, mesothelioma, and glioblastoma, cancers known for their resistance to existing treatments. Genprex's CEO, Ryan Confer, expressed optimism about the data, highlighting the established role of the TUSC2 gene in lung cancer and the expansion of Reqorsa's use for other cancer indications.
Following these presentations, Genprex has filed two provisional patent applications related to the use of Reqorsa in treating mesothelioma and glioblastoma. These filings are in partnership with the respective institutions involved in the research.
Reqorsa consists of a plasmid with the TUSC2 gene encapsulated in non-viral lipid nanoparticles, which is designed to target cancer cells specifically while minimizing impact on normal tissue. This therapy is part of Genprex's Oncoprex® Delivery System and is administered intravenously. Laboratory studies have shown a significantly higher uptake of TUSC2 in tumor cells compared to normal cells after treatment with Reqorsa.
Genprex's ongoing clinical trials are evaluating Reqorsa for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with both programs having received Fast Track Designation from the FDA. Additionally, the SCLC program has been granted an FDA Orphan Drug Designation.
In other recent news, Genprex, Inc. has made significant strides in its gene therapy research. The company has initiated a collaboration with the University of Michigan Rogel Cancer Center and the non-profit group ALK Positive to study potential treatments for ALK-EML4 positive translocated lung cancer. The research focuses on the TUSC2 gene and its potential in combination with ALK-inhibitors.
Genprex's recent positive preclinical results for Reqorsa® Gene Therapy are reflected in the company's recent market performance. According to InvestingPro data, Genprex has seen a significant return of 31.13% over the last week and an impressive 433.69% over the last month. This surge in stock price aligns with the optimism surrounding the company's recent announcements at the EORTC-NCI-AACR Symposium.
